The Saudi Food and Drug Authority (SFDA) has issued an emergency warning against using the drug Aclasta as it may cause nephrosis for patients who are suffering renal failure. It also has issued the warning to the elderly or those using products that affect kidney functions such as diuretics or those who suffer from dehydration. Aclasta is used for the treatment of osteoporosis in postmenopausal women to reduce the incidence of fractures and to increase bone mineral density. The SFDA announced that the manufacturer of Aclasta would send messages to all health practitioners and warn them of the risks of Aclasta causing nephrosis. It will include this risk in the side-effects sheet.” The SFDA also urged doctors not to prescribe the drug for patients who are using other products that affect the renal functions. Patients who have renal problems or dehydration secondary to fever or sepsis or loss of significant food elements and liquids through the digestive system are at higher risk of chronic renal failure; therefore, the dose they take should not exceed 5 mg.
